This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Axsome's AXS-05 Meets Goal in Phase II Study, Shares Up
by Zacks Equity Research
Axsome's (AXSM) mid-stage candidate, AXS-05, achieves the primary endpoint in a phase II study as a smoking cessation treatment. Shares rise.
Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA
by Zacks Equity Research
The FDA accepts Novartis' (NVS) BLA seeking approval for brolucizumab for the treatment of wet AMD.
Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer
by Zacks Equity Research
Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.
Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group
by Zacks Equity Research
Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal
by Kinjel Shah
Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon
by Zacks Equity Research
Novartis' (NVS) Sandoz signs an agreement with Japanese company, Shionogi, to commercialize constipation drug in key European markets.
AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer
by Zacks Equity Research
AstraZeneca (AZN) and Merck gain an EU approval for Lynparza as a monotherapy for treating HER2-negative locally-advanced/metastatic breast cancer.
Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth
by Zacks Equity Research
Emergent's (EBS) vaccine portfolio looks promising. The company's recent acquisitions also bode well for growth.
Glaxo's Dovato Gets FDA Nod for Treatment-Naive HIV Patients
by Zacks Equity Research
Glaxo's (GSK) ViiV Healthcare gets FDA approval for a single-tablet two-drug regimen (2DR), Dovato for treatment naive HIV- 1 adults.
Gilead Files sNDA for Label Expansion of HIV Therapy Descovy
by Zacks Equity Research
Gilead (GILD) submits sNDA to the FDA for label expansion of Descovy as PrEP to reduce the risk of sexually acquired HIV-1 infection.
Health Day Checkup of Medical ETFs: 5 Top Picks
by Sanghamitra Saha
M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.
Novartis Resubmits BLA to FDA for Biosimilar of Neulasta
by Zacks Equity Research
Novartis' (NVS) generic arm Sandoz resubmits its BLA for the proposed biosimilar of Neulasta.
Clovis Posts Data on Rubraca Study for Pancreatic Cancer
by Zacks Equity Research
Clovis (CLVS) presents interim data from the phase II study on Rubraca for the first-line maintenance treatment of patients with advanced pancreatic cancer.
Novartis Gets Approval for Psoriasis Drug Cosentyx in China
by Zacks Equity Research
Novartis' (NVS) psoriasis drug gets approval in China. The company also signs an agreement to expand its biologics therapy manufacturing capability.
Merck's Keytruda Gets Nod for First-Line Lung Cancer in China
by Zacks Equity Research
Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting in China.
3 Big Pharma Stocks to Add to Your Portfolio This April
by Kinjel Shah
The large-cap pharma industry is on a strong footing in 2019. Here are three stocks from the space that investors may consider betting on.
Top Analyst Reports for Chevron, IBM & Medtronic
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), IBM (IBM) and Medtronic (MDT).
Axsome's Depression Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
Axsome (AXSM) announces that the FDA has granted Breakthrough Therapy designation to AXS-05 for the treatment of major depressive disorder (MDD).
5 Cancer-Fighting Stocks to Boost Portfolio Gains
by Swarup Gupta
It would pay to invest in these companies which offer current franchises or prospective treatments for the most dreaded of diseases.
Emergent Begins Phase III Study on Anthrax Vaccine AV7909
by Zacks Equity Research
Emergent (EBS) kicks off a late-stage study on its investigational anthrax vaccine AV7909.
Glaxo Presents Encouraging Data on Endometrial Cancer Drug
by Zacks Equity Research
Glaxo (GSK) presents encouraging data from phase I/II study on endometrial cancer drug, dostarlimab.
Novartis' (NVS) Alcon Acquired PowerVision for $285 Million
by Zacks Equity Research
Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.
GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $40.03 in the latest trading session, marking a -0.12% move from the prior day.
Should Value Investors Pick GlaxoSmithKline (GSK) Stock Now?
by Zacks Equity Research
Let's see if GlaxoSmithKline (GSK) stock is a good choice for value-oriented investors right now from multiple angles.
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
by Zacks Equity Research
Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.